DK3520805T3 - Sammensætninger til behandling af myelofibrose - Google Patents

Sammensætninger til behandling af myelofibrose Download PDF

Info

Publication number: DK3520805T3
Authority: DK; Denmark
Prior art keywords: myelofibrose; compositions; treatment
Prior art date: 2011-10-17

Application number

DK19161424.7T

Other languages

English (en)

Inventor

Jasbir Seehra

Robert Scott Pearsall

Ravindra Kumar

Naga Venkata Sai Rajasekhar Suragani

Original Assignee

Acceleron Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-17

Filing date

2012-10-17

Publication date

2021-04-19

2012-10-17 Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc

2021-04-19 Application granted granted Critical

2021-04-19 Publication of DK3520805T3 publication Critical patent/DK3520805T3/da

Links

239000000203 mixture Substances 0.000 title 1
206010028537 myelofibrosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Endocrinology (AREA)
Mycology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK19161424.7T 2011-10-17 2012-10-17 Sammensætninger til behandling af myelofibrose DK3520805T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161547932P	2011-10-17	2011-10-17
EP12842601.2A EP2797620B1 (en)	2011-10-17	2012-10-17	Compositions for treating iron overload in thalassemia

Publications (1)

Publication Number	Publication Date
DK3520805T3 true DK3520805T3 (da)	2021-04-19

Family

ID=48141315

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19161424.7T DK3520805T3 (da)	2011-10-17	2012-10-17	Sammensætninger til behandling af myelofibrose
DK21153891.3T DK3875104T3 (da)	2011-10-17	2012-10-17	Sammensætninger til behandling af ineffektiv erytropoiese

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK21153891.3T DK3875104T3 (da)	2011-10-17	2012-10-17	Sammensætninger til behandling af ineffektiv erytropoiese

Country Status (13)

Country	Link
US (4)	US20130243743A1 (da)
EP (3)	EP2797620B1 (da)
JP (4)	JP6092883B2 (da)
KR (4)	KR20140084211A (da)
CN (3)	CN107837390A (da)
AU (4)	AU2012326207B2 (da)
BR (3)	BR122019023174B1 (da)
CA (1)	CA2852683A1 (da)
DK (2)	DK3520805T3 (da)
EA (2)	EA034563B1 (da)
ES (3)	ES3010483T3 (da)
HK (2)	HK1250341A1 (da)
WO (1)	WO2013059347A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3489257A1 (en)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
EP2781222B1 (en)	2005-11-23	2017-08-02	Acceleron Pharma, Inc.	Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en)	2007-02-01	2008-08-07	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en)	2007-02-09	2019-09-11	Acceleron Pharma Inc.	Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja)	2007-09-18	2010-12-16	アクセルロンファーマ，インコーポレイテッド	アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
JP5912078B2 (ja)	2009-06-08	2016-04-27	アクセルロンファーマ，インコーポレイテッド	熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en)	2009-06-12	2020-09-02	Acceleron Pharma Inc.	Truncated actriib-fc fusion proteins
JP6211767B2 (ja) *	2009-09-09	2017-10-11	アクセルロンファーマ，インコーポレイテッド	ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
EP3332796A1 (en)	2009-11-17	2018-06-13	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
KR20130132824A (ko)	2010-11-08	2013-12-05	악셀레론 파마 인코포레이티드	Actriia 결합제 및 이의 용도
WO2013055476A1 (en)	2011-09-09	2013-04-18	Anthrogenesis Corporation	Treatment of amyotrophic lateral sclerosis using placental stem cells
US10195249B2 (en)	2012-11-02	2019-02-05	Celgene Corporation	Activin-ActRII antagonists and uses for treating bone and other disorders
EP3119418B1 (en) *	2014-03-21	2022-02-23	Acceleron Pharma Inc.	Composition for use in a method of treating or preventing anemia by inhibiting activin b and gdf11
BR112016024319B1 (pt) *	2014-04-18	2024-01-23	Acceleron Pharma Inc	USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
MA40008A (fr)	2014-06-13	2021-05-05	Acceleron Pharma Inc	Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr)	2014-12-03	2017-10-10	Acceleron Pharma Inc	Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
TWI730949B (zh) *	2014-12-03	2021-06-21	美商西建公司	活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
SI3286206T1 (sl)	2015-04-22	2021-07-30	Biogen Ma Inc.	Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
JP6976859B2 (ja) *	2015-05-13	2021-12-08	セルジーンコーポレイション	ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
EP3298034A4 (en)	2015-05-20	2019-02-13	Celgene Corporation	IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
EP3370754B1 (en) *	2015-11-04	2026-04-29	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en)	2015-11-23	2017-06-01	Acceleron Pharma Inc.	Methods for treating eye disorders
HUE067225T2 (hu)	2016-07-27	2024-10-28	Acceleron Pharma Inc	Mielofibrózis kezelésére szolgáló készítmények
KR102761094B1 (ko)	2016-10-05	2025-02-03	악셀레론 파마 인코포레이티드	변이체 actriib 단백질 및 이의 용도
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN119241685A (zh)	2016-11-10	2025-01-03	科乐斯疗法公司	激活素受体iia型变体及其使用方法
HUE068733T2 (hu)	2017-06-14	2025-01-28	Celgene Corp	Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére
CN111801112A (zh)	2017-11-09	2020-10-20	科乐斯疗法公司	激活素受体iia型变体及其使用方法
KR20200109330A (ko)	2018-01-12	2020-09-22	케로스 테라퓨틱스, 인크.	액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
WO2019217715A1 (en)	2018-05-09	2019-11-14	Keros Therapeutics, Inc.	Activin receptor type iia variants and methods of use thereof
JP2022549506A (ja)	2019-09-27	2022-11-25	ディスク・メディシン・インコーポレイテッド	骨髄線維症および関連状態を処置するための方法
EP4121088A4 (en)	2020-03-20	2024-07-03	Keros Therapeutics, Inc.	Methods of using activin receptor type iib variants
CA3176735A1 (en)	2020-03-20	2021-09-23	Keros Therapeutics, Inc.	Activin receptor type ii chimeras and methods of use thereof
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en)	2020-11-05	2025-01-07	Celgene Corporation	ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1265208A (en)	1915-09-07	1918-05-07	Edward C Kahn	Liquid-fuel burner.
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en)	1989-02-03	1990-08-09	Genetics Institute, Inc.	Erythropoietin receptor
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
US5677196A (en)	1993-05-18	1997-10-14	University Of Utah Research Foundation	Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en)	1994-03-29	1996-06-11	Onyx Pharmaceuticals, Inc.	Reverse two-hybrid method
US5885574A (en)	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
US5814565A (en)	1995-02-23	1998-09-29	University Of Utah Research Foundation	Integrated optic waveguide immunosensor
NZ502795A (en)	1995-04-11	2001-09-28	Gen Hospital Corp	Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5807839A (en) *	1997-04-15	1998-09-15	Advanced Viral Research Corp.	Method for stimulating red blood cell production
NZ513642A (en)	1999-01-21	2004-02-27	Metamorphix Inc	Growth differentiation factor inhibitors and uses therefor
US7842691B2 (en) *	2002-10-15	2010-11-30	Celgene Corporation	Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
EP3489257A1 (en)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
US8067562B2 (en)	2005-11-01	2011-11-29	Amgen Inc.	Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) *	2006-12-18	2010-02-04	Acceleron Pharma Inc.	Antagonists of actriib and uses for increasing red blood cell levels
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
US8216997B2 (en) *	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) *	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
CN102655872B (zh) *	2009-08-13	2016-01-20	阿塞勒隆制药公司	Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

2012
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Ceased
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en not_active Ceased
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active Ceased
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/en active Active
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active Active
- 2012-10-17 EP EP21153891.3A patent/EP3875104B1/en active Active
- 2012-10-17 ES ES21153891T patent/ES3010483T3/es active Active
- 2012-10-17 DK DK21153891.3T patent/DK3875104T3/da active
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Ceased
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/en active Active
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2017201580B2 (en)	2018-07-12
HK1203413A1 (en)	2015-10-30
ES2869168T3 (es)	2021-10-25
EA202090053A3 (ru)	2020-06-30
BR112014009528B1 (pt)	2020-12-29
EA201490809A1 (ru)	2014-09-30
KR20200019261A (ko)	2020-02-21
AU2018247262A1 (en)	2018-11-01
HK1250341A1 (zh)	2018-12-14
KR102079482B1 (ko)	2020-02-19
US20210207107A1 (en)	2021-07-08
ES3010483T3 (en)	2025-04-03
CN107837390A (zh)	2018-03-27
JP2014530253A (ja)	2014-11-17
CN107693776A (zh)	2018-02-16
AU2012326207A1 (en)	2014-05-15
EP3520805A1 (en)	2019-08-07
BR112014009528A2 (pt)	2017-05-09
JP6092883B2 (ja)	2017-03-08
KR20190105113A (ko)	2019-09-11
CA2852683A1 (en)	2013-04-25
EP2797620B1 (en)	2019-04-24
AU2012326207B2 (en)	2016-12-15
EA034563B1 (ru)	2020-02-20
EA202090053A2 (ru)	2020-04-30
ES2741477T3 (es)	2020-02-11
JP2020186277A (ja)	2020-11-19
EP3875104A1 (en)	2021-09-08
BR112014009528A8 (pt)	2019-12-10
AU2018247262B2 (en)	2020-12-24
BR122019023174B1 (pt)	2021-02-23
US20170137791A1 (en)	2017-05-18
CN103987403A (zh)	2014-08-13
JP2017101060A (ja)	2017-06-08
AU2017201580A1 (en)	2017-03-30
EP2797620A1 (en)	2014-11-05
KR20220075438A (ko)	2022-06-08
WO2013059347A1 (en)	2013-04-25
BR122019023166B1 (pt)	2021-02-23
EP3875104B1 (en)	2025-01-22
EP2797620A4 (en)	2015-05-20
EP3520805B1 (en)	2021-03-10
JP6383821B2 (ja)	2018-08-29
US20130243743A1 (en)	2013-09-19
HK1252940A1 (zh)	2019-06-06
DK3875104T3 (da)	2025-02-03
KR20140084211A (ko)	2014-07-04
JP2018165287A (ja)	2018-10-25
JP6796626B2 (ja)	2020-12-09
AU2020286229A1 (en)	2021-01-07
CN103987403B (zh)	2017-12-01
US20170327800A1 (en)	2017-11-16

Publication	Publication Date	Title
EP2736491A4 (en)	2014-07-09	BEPOTASTIN COMPOSITION
DK2635282T3 (da)	2022-10-17	Sammensætninger til behandling af myelofibrose
EP2675909A4 (en)	2016-11-30	GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en)	2015-04-08	Stevia-COMPOSITION
EP2713762A4 (en)	2014-11-26	Stevia-COMPOSITION
LT2791160T (lt)	2022-06-10	Modifikuotos mrnr sudėtys
DK2872152T3 (da)	2019-12-02	Acellulære pro-tolerogene sammensætninger til behandling/forebyggelse af transplantatafstødning
LT2742151T (lt)	2018-02-12	Polimerazės kompozicija
BR112013022112A2 (pt)	2018-06-26	composição
DK3875104T3 (da)	2025-02-03	Sammensætninger til behandling af ineffektiv erytropoiese
DK2686017T3 (da)	2019-10-07	Oftalmisk sammensætning
BR112014004395A2 (pt)	2017-03-28	composição
DK2739293T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2701733T3 (da)	2019-05-27	Forbindelser til behandling af neuropsykiatriske forstyrrelser
CO6930368A2 (es)	2014-04-28	Composiciones de yodo-povidona estable
SI3513806T1 (sl)	2023-04-28	Sestava imunogena
EP2800124A4 (en)	2015-08-12	POLISHING COMPOSITION
DK2836460T3 (da)	2022-10-10	Fremgangsmåde til fremstilling af graphen
DK2822568T3 (da)	2020-08-10	Anvendelser af caseinsammensætninger
BR112013033808A2 (pt)	2017-02-14	composição
DK2734212T3 (da)	2017-11-06	Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
DK3444238T3 (da)	2022-01-03	Fremgangsmåde til fremstilling af difluormethylenforbindelser
EP2730619A4 (en)	2015-02-18	COMPOSITION
IL231907B (en)	2018-05-31	Compounds and compositions for treatment of transthyretin-associated amyloidosis
PT2739276T (pt)	2019-05-27	Composição antisséptica